vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and Star Equity Holdings, Inc. (STRR). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $56.8M, roughly 1.3× Star Equity Holdings, Inc.). Star Equity Holdings, Inc. runs the higher net margin — -3.0% vs -121.9%, a 118.9% gap on every dollar of revenue. On growth, Star Equity Holdings, Inc. posted the faster year-over-year revenue change (69.0% vs -6.2%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-9.0M). Over the past eight quarters, Star Equity Holdings, Inc.'s revenue compounded faster (29.5% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

Artists Equity is an American production company founded by actors and filmmakers Ben Affleck and Matt Damon in November 2022.

HCAT vs STRR — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.3× larger
HCAT
$74.7M
$56.8M
STRR
Growing faster (revenue YoY)
STRR
STRR
+75.2% gap
STRR
69.0%
-6.2%
HCAT
Higher net margin
STRR
STRR
118.9% more per $
STRR
-3.0%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$18.6M more FCF
HCAT
$9.6M
$-9.0M
STRR
Faster 2-yr revenue CAGR
STRR
STRR
Annualised
STRR
29.5%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCAT
HCAT
STRR
STRR
Revenue
$74.7M
$56.8M
Net Profit
$-91.0M
$-1.7M
Gross Margin
Operating Margin
-115.3%
-0.2%
Net Margin
-121.9%
-3.0%
Revenue YoY
-6.2%
69.0%
Net Profit YoY
-340.3%
-192.1%
EPS (diluted)
$-1.29
$-0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
STRR
STRR
Q4 25
$74.7M
$56.8M
Q3 25
$76.3M
$48.0M
Q2 25
$80.7M
$35.5M
Q1 25
$79.4M
$31.9M
Q4 24
$79.6M
$33.6M
Q3 24
$76.4M
$36.9M
Q2 24
$75.9M
$35.7M
Q1 24
$74.7M
$33.9M
Net Profit
HCAT
HCAT
STRR
STRR
Q4 25
$-91.0M
$-1.7M
Q3 25
$-22.2M
$-1.8M
Q2 25
$-41.0M
$-688.0K
Q1 25
$-23.7M
$-1.8M
Q4 24
$-20.7M
$-585.0K
Q3 24
$-14.7M
$-846.0K
Q2 24
$-13.5M
$-441.0K
Q1 24
$-20.6M
$-2.9M
Gross Margin
HCAT
HCAT
STRR
STRR
Q4 25
Q3 25
52.6%
43.0%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
50.5%
Q2 24
Q1 24
Operating Margin
HCAT
HCAT
STRR
STRR
Q4 25
-115.3%
-0.2%
Q3 25
-22.9%
-3.4%
Q2 25
-46.0%
-0.6%
Q1 25
-25.4%
-5.4%
Q4 24
-22.0%
-0.4%
Q3 24
-17.9%
-1.2%
Q2 24
-20.8%
-0.5%
Q1 24
-30.5%
-9.0%
Net Margin
HCAT
HCAT
STRR
STRR
Q4 25
-121.9%
-3.0%
Q3 25
-29.1%
-3.7%
Q2 25
-50.8%
-1.9%
Q1 25
-29.9%
-5.5%
Q4 24
-26.0%
-1.7%
Q3 24
-19.3%
-2.3%
Q2 24
-17.8%
-1.2%
Q1 24
-27.6%
-8.6%
EPS (diluted)
HCAT
HCAT
STRR
STRR
Q4 25
$-1.29
$-0.49
Q3 25
$-0.32
$-0.54
Q2 25
$-0.59
$-0.23
Q1 25
$-0.35
$-0.59
Q4 24
$-0.33
$-0.21
Q3 24
$-0.24
$-0.28
Q2 24
$-0.23
$-0.15
Q1 24
$-0.35
$-0.95

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
STRR
STRR
Cash + ST InvestmentsLiquidity on hand
$95.7M
$10.3M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
$65.7M
Total Assets
$502.6M
$113.2M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
STRR
STRR
Q4 25
$95.7M
$10.3M
Q3 25
$91.5M
$15.4M
Q2 25
$97.3M
$16.8M
Q1 25
$342.0M
$16.6M
Q4 24
$392.0M
$17.0M
Q3 24
$387.3M
$15.8M
Q2 24
$308.3M
$14.7M
Q1 24
$327.8M
$20.4M
Total Debt
HCAT
HCAT
STRR
STRR
Q4 25
$153.3M
Q3 25
$153.1M
$6.5M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
$0
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
HCAT
HCAT
STRR
STRR
Q4 25
$245.8M
$65.7M
Q3 25
$331.9M
$67.8M
Q2 25
$347.5M
$40.1M
Q1 25
$376.8M
$39.5M
Q4 24
$365.2M
$40.4M
Q3 24
$355.0M
$42.9M
Q2 24
$357.0M
$42.6M
Q1 24
$357.2M
$44.3M
Total Assets
HCAT
HCAT
STRR
STRR
Q4 25
$502.6M
$113.2M
Q3 25
$587.1M
$117.1M
Q2 25
$616.2M
$55.6M
Q1 25
$891.5M
$53.2M
Q4 24
$858.9M
$52.6M
Q3 24
$813.0M
$52.6M
Q2 24
$691.7M
$52.6M
Q1 24
$695.1M
$52.6M
Debt / Equity
HCAT
HCAT
STRR
STRR
Q4 25
0.62×
Q3 25
0.46×
0.10×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
0.00×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
STRR
STRR
Operating Cash FlowLast quarter
$9.9M
$-7.3M
Free Cash FlowOCF − Capex
$9.6M
$-9.0M
FCF MarginFCF / Revenue
12.9%
-15.8%
Capex IntensityCapex / Revenue
0.4%
3.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K
$-13.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
STRR
STRR
Q4 25
$9.9M
$-7.3M
Q3 25
$-464.0K
$-2.7M
Q2 25
$-9.0M
$139.0K
Q1 25
$280.0K
$-802.0K
Q4 24
$-3.5M
$-2.8M
Q3 24
$6.2M
$1.3M
Q2 24
$1.6M
$-4.3M
Q1 24
$10.3M
$-1.8M
Free Cash Flow
HCAT
HCAT
STRR
STRR
Q4 25
$9.6M
$-9.0M
Q3 25
$-719.0K
$-3.4M
Q2 25
$-9.2M
$102.0K
Q1 25
$-390.0K
$-808.0K
Q4 24
$-3.9M
$-2.8M
Q3 24
$5.5M
$1.3M
Q2 24
$1.3M
$-4.3M
Q1 24
$10.1M
$-1.8M
FCF Margin
HCAT
HCAT
STRR
STRR
Q4 25
12.9%
-15.8%
Q3 25
-0.9%
-7.0%
Q2 25
-11.4%
0.3%
Q1 25
-0.5%
-2.5%
Q4 24
-4.9%
-8.3%
Q3 24
7.2%
3.4%
Q2 24
1.7%
-12.0%
Q1 24
13.5%
-5.3%
Capex Intensity
HCAT
HCAT
STRR
STRR
Q4 25
0.4%
3.0%
Q3 25
0.3%
1.3%
Q2 25
0.3%
0.1%
Q1 25
0.8%
0.0%
Q4 24
0.5%
0.1%
Q3 24
0.9%
0.0%
Q2 24
0.4%
0.0%
Q1 24
0.3%
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

STRR
STRR

Revenue From Other Contracts With Customers$27.6M49%
Other$24.3M43%
Energy Services Segment$4.9M9%

Related Comparisons